Skip to content

Leena Gandhi

Dana-Farber Cancer Institute

3 papers in the Anchorcite directory, published between 2010 and 2018, cited 17,528 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Enriqueta Felip · 2 papers
  • Rina Hui · 2 papers
  • Edward B. Garon · 2 papers
  • Delvys Rodríguez‐Abreu · 1 paper
  • Shirish M. Gadgeel · 1 paper
  • Emilio Esteban · 1 paper
  • Flávia De Angelis · 1 paper
  • Manuel Dómine · 1 paper

Papers

  1. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations

    BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…

  2. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations

    BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…

  3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations

    BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in…

Metadata from OpenAlex (CC0).